BOULDER, Colo.--(BUSINESS WIRE)--Feb. 12, 2018--
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter
and full year 2017 financial results on Monday, February 26, 2018, after
the close of the U.S. financial markets. Clovis’ senior management will
host a conference call and live audio webcast at 4:30 p.m. ET to discuss
the company’s results in greater detail.
The conference call is being webcast and can be accessed from the Clovis
Oncology website at www.clovisoncology.com.
A replay of the webcast will be available for 30 days.
Conference Call Details
Clovis will hold a conference call to discuss fourth quarter and full
year 2017 results on February 26 at 4:30 p.m. ET. The conference call
will be simultaneously webcast on the Company’s web site at www.clovisoncology.com,
and archived for future review. Dial-in numbers for the conference call
are as follows: US participants 866.489.9022, International participants
678.509.7575, conference ID: 3097118.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on
acquiring, developing and commercializing innovative anti-cancer agents
in the U.S., Europe and additional international markets. Clovis
Oncology targets development programs at specific subsets of cancer
populations, and simultaneously develops, with partners, diagnostic
tools that direct a compound in development to the population that is
most likely to benefit from its use. Clovis Oncology is headquartered in
Boulder, Colorado, and has additional offices in San Francisco,
California and Cambridge, UK.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180212005035/en/
Source: Clovis Oncology, Inc.
Clovis Oncology, Inc.
Breanna Burkart, 303-625-5023